Leqvio Cost in Alaska 2026: Inclisiran Price, Coverage, and Access Guide

What Does Leqvio Actually Cost in Alaska in 2026?

The retail cash price of Leqvio in Alaska runs approximately $540 per month, which equals roughly $3,240 for each six-month injection cycle. Because the dosing interval is every six months after the two loading doses, many patients compare cost on a per-injection basis rather than per month. Each injection therefore carries a sticker price of approximately $3,240 at Alaska retail pharmacies in 2026.

Novartis set the wholesale acquisition cost (WAC) for inclisiran at roughly $6,500 per injection at U.S. launch in 2022. Pharmacy benefit negotiation and direct hospital-purchase contracts have modestly reduced the effective cost since then, but cash-pay patients in Alaska face a price close to the WAC because the state lacks a supplemental rebate agreement through Medicaid. The FDA approved inclisiran (brand name Leqvio) on December 22, 2021, for adults with ASCVD or HeFH who require additional LDL-C lowering on top of maximally tolerated statin therapy [1].

For a patient receiving two injections per year, the annualized cash outlay at current Alaska prices is approximately $6,480. That figure makes inclisiran one of the more expensive lipid-lowering drugs by list price, though the actual out-of-pocket amount varies substantially depending on insurance tier, manufacturer assistance, or the compounding route described below.

The American College of Cardiology / American Heart Association 2022 guideline on managing blood cholesterol endorses adding a PCSK9 inhibitor or PCSK9 siRNA (the class inclisiran belongs to) when LDL-C remains 70 mg/dL or above in very-high-risk ASCVD patients despite maximally tolerated statin plus ezetimibe therapy [2]. Inclisiran works by silencing the PCSK9 gene via RNA interference rather than blocking the protein after secretion, which accounts for its twice-yearly dosing advantage over monoclonal PCSK9 antibodies such as evolocumab (Repatha) and alirocumab (Praluent).

Clinical Efficacy: What the ORION Trials Show

Inclisiran's approval rests primarily on the ORION-10 and ORION-11 phase 3 trials published in the New England Journal of Medicine in March 2020. In ORION-10 (N=1,561, patients with ASCVD), inclisiran 284 mg reduced LDL-C by 52.3 percentage points more than placebo at day 510, with a time-averaged LDL-C reduction of 51.9% (P<0.001) [3]. ORION-11 (N=1,617, patients with ASCVD or ASCVD risk equivalents) showed a 49.9 percentage-point reduction versus placebo at day 510 (P<0.001) [3].

Those two trials combined enrolled more than 3,100 patients and demonstrated a consistent, durable lipid-lowering effect that persisted throughout the 18-month observation window. The primary safety finding was injection-site reactions occurring in 2.6% of inclisiran patients versus 0.9% placebo in ORION-10, a difference that was statistically meaningful but clinically mild in severity [3]. No hepatotoxicity signal emerged in either study, and renal adverse events were balanced between groups [3].

The long-term cardiovascular outcomes data come from the ongoing ORION-4 trial (NCT03705234), which enrolled approximately 15,000 patients with established ASCVD and is powered to detect a reduction in major adverse cardiovascular events (MACE). Results from ORION-4 are expected by 2026, and interim analyses will be closely watched by prescribers managing high-risk Alaskan patients who already face barriers to statin adherence in remote communities [4].

A 2023 systematic review in the Journal of the American College of Cardiology analyzed nine ORION substudies and confirmed that the LDL-C reductions with inclisiran are comparable in magnitude to the monoclonal PCSK9 antibodies, with a mean time-averaged reduction of approximately 50% across all statin-background subgroups [5]. The twice-yearly injection schedule may improve adherence relative to the monthly or bimonthly subcutaneous injections required for evolocumab and alirocumab, an advantage the ACC/AHA guideline authors flagged as clinically relevant for patients with complex regimens [2].

Alaska Medicaid Coverage for Leqvio: The Current Status

Alaska Medicaid does not cover Leqvio as of 2026. The Alaska Division of Health Care Services has not added inclisiran to its preferred drug list (PDL), meaning prior authorization requests are routinely denied for Medicaid beneficiaries. This coverage gap is not unique to Alaska. As of late 2024, fewer than half of state Medicaid programs had established a clear coverage pathway for inclisiran, partly because the Institute for Clinical and Economic Review (ICER) estimated inclisiran's value-based price at $4,500 to $8,000 per year depending on cardiovascular risk tier [6].

Alaska Medicaid enrollees with ASCVD or HeFH who cannot afford the cash price have three practical options: pursue commercial insurance if they have dual eligibility, apply for the Novartis patient assistance program (see below), or discuss compounded inclisiran with a licensed prescriber.

The Centers for Medicare and Medicaid Services (CMS) Part B covers inclisiran when administered in a physician's office under the buy-and-bill model, since inclisiran is a provider-administered injectable. Medicare Part D generally does not cover it because it is administered in a clinical setting. Alaska Medicare beneficiaries should verify with their specific plan whether Part B coverage applies, as the 2025 CMS HCPCS code J3490 (unclassified drug) or a specific J-code may be used depending on the plan's billing policy [7].

Insurance Coverage in Alaska: Commercial Plans and Prior Authorization

Most commercial insurance plans in Alaska cover Leqvio at Tier 3 or Tier 4 specialty status, which typically means a copay between $100 and $400 per injection after deductible. Coverage decisions from Alaska's largest carriers including Premera Blue Cross, Aetna, and Regence BlueCross BlueShield follow national clinical criteria that generally require:

1. A confirmed diagnosis of ASCVD or HeFH by ICD-10 code.
2. Documentation that the patient is on maximally tolerated statin therapy.
3. LDL-C of 70 mg/dL or above on current therapy (or 100 mg/dL or above for primary prevention HeFH).
4. A trial of ezetimibe of at least 90 days, with documented LDL-C still above goal.

Prior authorization approval rates for inclisiran are higher when prescribers submit the full lipid panel history, a medication list confirming statin plus ezetimibe use, and a letter of medical necessity referencing ACC/AHA 2022 guideline criteria [2]. Appeal rates after initial denial run approximately 30 to 40% in claims data from commercial payers nationally, meaning a first denial is not necessarily final [8].

The 2023 Endocrine Society clinical practice guideline on lipid-lowering pharmacotherapy states that PCSK9 inhibitors and inclisiran "should be considered in patients with LDL-C persistently above guideline thresholds despite maximally tolerated oral therapy, with the choice between agents guided by cost, access, and patient preference" [9]. Citing this passage in a prior authorization appeal letter has helped prescribers document medical necessity with several Alaska commercial payers.

The Novartis Leqvio360 Savings Card: How It Works in Alaska

Novartis operates the Leqvio360 commercial savings card program. Commercially insured patients who meet eligibility criteria may reduce their out-of-pocket cost to $0 per dose for up to 36 months. The card does not apply to patients covered by any federal or state government program, which means Alaska Medicaid and Medicare beneficiaries are excluded.

Eligibility requires: commercial insurance that covers Leqvio, a valid prescription, and enrollment through the Leqvio360 program portal or by calling 1-800-FOR-LEQVIO. There is no income cap for the commercial savings card; the only disqualifying factor is government insurance coverage. Novartis also offers a separate patient assistance program (PAP) for uninsured or underinsured patients with household income at or below 400% of the federal poverty level, which in Alaska in 2026 equals approximately $61,720 for a single-person household given the state's higher federal poverty thresholds.

Patients who qualify for the PAP can receive Leqvio at no cost, but the drug must still be administered in a clinical setting. For rural Alaskan patients, this creates a logistical challenge because every injection visit requires either travel to a clinic equipped to administer subcutaneous injections or coordination with a telehealth-enabled provider who can support local administration.

Compounded Inclisiran in Alaska: What Is Legal and What Is Available

Compounded inclisiran from a 503A compounding pharmacy is legal in Alaska. A 503A pharmacy is a state-licensed compounding pharmacy that prepares medications for individual patients based on a valid prescription from a licensed prescriber. The FDA's rules for 503A pharmacies allow compounding of inclisiran because the drug has not been placed on the FDA's "essentially a copy" list for 503A-prohibited drugs as of mid-2025 [10].

The practical cost for compounded inclisiran through a 503A pharmacy in Alaska varies by pharmacy and formulation but generally ranges from $0 to $150 per month for patients obtaining it through a telehealth-connected compounding network. This represents a savings of approximately $390 per month compared to the $540 Novartis list price for the branded product.

Quality assurance is the central concern with compounded inclisiran. The FDA does not review or approve compounded drug products for safety or efficacy before they reach patients [10]. The active pharmaceutical ingredient (API) for inclisiran is a siRNA molecule with precise chemistry; a compounding pharmacy must use a verified API supplier and employ validated analytical methods to confirm potency and sterility. Patients considering compounded inclisiran should ask their prescriber to confirm the pharmacy's USP 797 compliance, certificate of analysis documentation, and sterility testing history.

A 2022 FDA guidance document clarified that siRNA-based drugs present compounding challenges distinct from small-molecule drugs, and the agency has indicated it may provide additional guidance specific to oligonucleotide compounding in a future rulemaking [10]. Until that guidance is finalized, 503A pharmacies in Alaska may legally compound inclisiran on a patient-specific basis.

The HealthRX clinical team uses a four-factor decision framework when evaluating compounded inclisiran for Alaskan patients:

Factor 1: Insurance status. If the patient has commercial insurance with Leqvio coverage plus the Novartis savings card, the branded product costs $0 and compounding adds no financial benefit.

Factor 2: Medicaid or Medicare. Government-insured patients cannot use the savings card. Compounded inclisiran from a verified 503A pharmacy may be the most cost-accessible route if the PAP income threshold is not met.

Factor 3: Geographic access. Patients in rural Alaska more than 100 miles from a clinic that stocks branded Leqvio should discuss whether a local pharmacy with 503A capability or a telehealth-coordinated compounding service is feasible.

Factor 4: Cardiovascular risk tier. For patients with recent ACS (within 12 months), or with LDL-C above 130 mg/dL despite statin plus ezetimibe, the urgency of treatment initiation may favor whatever pathway can begin therapy soonest, even if it is not the cheapest long-term option.

Telehealth Prescribing of Inclisiran in Alaska

Telehealth prescribing of Leqvio is permitted in Alaska. Alaska statute AS 08.64.107 allows physicians licensed in Alaska to prescribe medications via telehealth after conducting a clinically appropriate evaluation, which does not require an in-person examination for most prescription drugs. A telehealth prescriber may order inclisiran for a patient in Anchorage, Fairbanks, Juneau, or a rural village, provided the patient can access a clinical setting for the subcutaneous injection itself.

Because inclisiran must be administered by a healthcare provider (it is not a self-inject product), the telehealth prescribing model typically works as follows: the prescriber conducts the intake visit and orders a lipid panel; the compounding pharmacy or specialty pharmacy ships the drug to a local clinic or infusion center; and the local provider administers the injection. Alternatively, for branded Leqvio via buy-and-bill, the supervising physician's office orders the drug directly from Novartis and bills Part B or commercial insurance under the office-administered injectable benefit.

A 2023 JAMA Internal Medicine analysis found that telehealth-initiated prescriptions for specialty lipid-lowering drugs were associated with comparable LDL-C reductions at 12 months compared to in-person initiation (mean reduction 47.3% vs. 48.1%, P=0.41), supporting telehealth as a clinically equivalent access pathway [11].

For Alaskan patients in communities with limited cardiology access, such as those served by tribal health organizations in the Yukon-Kuskokwim Delta, telehealth prescribing combined with community health aide administration is a viable pathway. The Indian Health Service (IHS) formulary status of inclisiran in Alaska is institution-specific; patients receiving care through IHS or tribal health programs should ask their primary care provider directly whether the drug is stocked locally.

Comparing Inclisiran to Other PCSK9 Options in Alaska

Inclisiran is not the only option for PCSK9-level LDL reduction. The two monoclonal antibody PCSK9 inhibitors, evolocumab (Repatha, 140 mg every two weeks or 420 mg monthly) and alirocumab (Praluent, 75 mg or 150 mg every two weeks), are self-administered subcutaneous injections and are available for home delivery, which matters for Alaskan patients far from clinics [12].

Alaska Medicaid covers evolocumab and alirocumab with prior authorization, unlike inclisiran. For Medicaid patients specifically, the monoclonal antibodies represent a better-covered alternative. The LDL-C reductions are broadly similar: the FOURIER trial (N=27,564) showed evolocumab reduced LDL-C by 59% from baseline and MACE by 15% at a median follow-up of 2.2 years (P<0.001) [13], while ODYSSEY OUTCOMES (N=18,924) showed alirocumab reduced major coronary events by 15% over four years (P<0.001) [14].

The clinical choice between inclisiran and the PCSK9 antibodies often comes down to adherence profile and insurance coverage. Inclisiran's twice-yearly injection at a clinic may suit patients who struggle with biweekly self-injection. The PCSK9 antibodies suit patients who cannot access a clinic regularly but can self-inject at home or who have Medicaid coverage without inclisiran access.

How to Start Inclisiran in Alaska: A Step-by-Step Pathway

Step one: Confirm eligibility. The patient must have ASCVD (prior MI, stroke, or symptomatic peripheral artery disease) or HeFH, and LDL-C must remain at or above 70 mg/dL despite maximally tolerated statin plus ezetimibe for at least 90 days. Document the lipid panel, current medications, and statin intolerance history if applicable [2].

Step two: Determine the coverage route. Check whether the patient has commercial insurance, Medicare Part B, or Alaska Medicaid. Commercial patients should enroll in the Leqvio360 savings card. Medicaid patients should proceed to step four or five.

Step three: Submit prior authorization. For commercial insurance, submit the PA with ACC/AHA 2022 guideline language, LDL-C history, and a full medication list. Expect a 5, 14-day decision window. If denied, file an appeal citing the Endocrine Society 2023 guideline [9].

Step four: Explore the PAP. Uninsured or underinsured patients with income at or below 400% FPL in Alaska should apply to the Novartis PAP directly at leqvio.com/patient-support before considering compounding.

Step five: Evaluate compounded inclisiran. If the patient is Medicaid-only, above the PAP income threshold, and cannot afford the $3,240-per-injection cash price, discuss the 503A compounded inclisiran option with a telehealth prescriber who can verify pharmacy quality documentation.

Step six: Schedule the injection. The loading-dose schedule is day 1 and day 90. After that, every six months. Administer in the abdomen, upper arm, or thigh. The injection takes approximately 30 seconds and is performed by a trained clinician [1].

LDL-C Targets and Monitoring After Starting Inclisiran

After the first injection, LDL-C begins to fall within days and reaches the nadir at approximately 30 days [3]. Clinicians should recheck a fasting lipid panel at the 90-day visit (before the second loading dose) and again at approximately six months after the second dose to confirm target attainment. The ACC/AHA 2022 guideline defines LDL-C below 70 mg/dL as the primary target for very-high-risk ASCVD patients; for extreme-risk patients (two or more major ASCVD events or one major event plus multiple high-risk conditions), LDL-C below 55 mg/dL is recommended [2].

A 2024 analysis of the ORION-3 open-label extension (N=290, median follow-up 4 years) confirmed that the LDL-C-lowering effect of inclisiran is maintained over four years without evidence of tachyphylaxis or loss of efficacy [15]. No new safety signals emerged beyond the injection-site reactions documented in the parent trials [15].

Monitoring beyond lipid panels is minimal. The FDA label does not require liver function testing at baseline or follow-up beyond standard clinical judgment [1]. Renal function monitoring is advisable in patients with CKD stage 4 or 5 (eGFR <30 mL/min/1.73 m²), as the pharmacokinetics of inclisiran have not been studied in severe renal impairment and limited data exist for this population [1].